Archive · 9 Jan 2026
Immuneel Partners to Expand CAR-T Cell Therapy Access
Immuneel Therapeutics, a company that makes a special treatment for certain blood cancers, has teamed up with two other companies to help more people get this treatment.
The treatment, called CAR-T cell therapy, is very expensive, costing about ₹35 lakh.
But it's a one-time treatment that can help patients a lot.
Immuneel has been working with hospitals and has seen good results.
Now, they want to make it easier for patients to pay for this treatment.
One company, Impact Guru, will help patients raise money from donors.
The other company, CarePal Money, will help patients get loans for their treatment.
This way, more people can get the treatment they need.
By March 2026, they hope to have helped about 100 patients.
Immuneel Therapeutics partners with Impact Guru and CarePal Money to expand access to CAR-T cell therapy.
CAR-T cell therapy is a personalized treatment for certain blood cancers, costing about ₹35 lakh.
Immuneel has treated patients with encouraging results and aims to help 100 patients by March 2026.
Impact Guru will mobilize funds through crowdfunding, while CarePal Money will facilitate structured credit.
The partnership aims to create a dual pathway for patients to access financial support for the treatment.
- Who
- Immuneel Therapeutics, Impact Guru, CarePal Money
- What
- Partnership to expand access to CAR-T cell therapy
- When
- January 9, 2026
- Where
- India
- Why
- To provide financing support for patients seeking expensive CAR-T cell therapy
- Company
- Immuneel Therapeutics
- Partners
- Impact Guru, CarePal Money
- Therapy Cost
- ₹35 lakh
- Target Patients
- Adult B-cell Non-Hodgkin Lymphoma
- Expected Patients by March 2026
- 100
- Founders
- Kiran Mazumdar Shaw, Siddhartha Mukherjee, Kush M Parmar
- Hospital Tie-ups
- 60 hospitals in India
- Impact Guru Donor Network
- Over 50 lakh contributors